Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Agrees To Propulsid Settlement

This article was originally published in The Pink Sheet Daily

Executive Summary

A Johnson & Johnson Propulsid litigation settlement will become effective once 85% of the death claims agree to its terms

You may also be interested in...



‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study

Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.

J&J To Pay Up To $15 Mil. To Settle Remaining Propulsid Cases

When combined with an earlier settlement agreement, J&J’s total liability for the bulk of the claims will be capped at $105 mil.

J&J To Pay Up To $15 Mil. To Settle Remaining Propulsid Cases

When combined with an earlier settlement agreement, J&J’s total liability for the bulk of the claims will be capped at $105 mil.

Topics

UsernamePublicRestriction

Register

PS058763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel